Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1A | P54750 | 18/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PDE1B | Q01064 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vinpocetine SCHEMBL20077503 | 1.00 | PDE1A (1.00) | PDE1AMEN1LMNAKMT2AHIF1A | |
| Vinpocetine SCHEMBL10571708 | 1.00 | PDE1A (1.00) | PDE1AMEN1LMNAKMT2AHIF1A | |
| Vinpocetine SCHEMBL6246968 | 1.00 | PDE1A (1.00) | PDE1AMEN1LMNAKMT2AHIF1A | |
| Vinpocetine SCHEMBL50081 | 1.00 | PDE1A (1.00) | PDE1AMEN1LMNAKMT2AHIF1A | |
| Vinpocetine SCHEMBL20077534 | 1.00 | PDE1A (1.00) | PDE1AMEN1LMNAKMT2AHIF1A | |
| Vinpocetine SCHEMBL160952 | 1.00 | PDE1A (1.00) | PDE1AMEN1LMNAKMT2AHIF1A | |
| Vinpocetine SCHEMBL7947532 | 1.00 | PDE1A (1.00) | PDE1AMEN1LMNAKMT2AHIF1A | |
| Vinpocetine SCHEMBL21370424 | 1.00 | PDE1A (1.00) | PDE1AMEN1LMNAKMT2AHIF1A | |
| Vinpocetine SCHEMBL21098929 | 1.00 | PDE1A (1.00) | PDE1AMEN1LMNAKMT2AHIF1A | |
| Vinpocetine SCHEMBL29366611 | 1.00 | PDE1A (1.00) | PDE1AMEN1LMNAKMT2AHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4058037-B1 | FIBROBLAST-BASED THERAPY FOR TREATMENT AND PREVENTION OF STROKE | SPINALCYTE LLC (US) | 2026-01-28 | — | — | EP | claimed |
| US-20250312340-A1 | METHODS OF TREATING NEUROPATHIC PAIN | INTRA-CELLULAR THERAPIES, INC. | 2025-10-09 | — | — | US | claimed |
| WO-2024125322-A1 | DIPYRIDAMOLE FOR PREVENTING AND TREATING ALLERGIC AND/OR INFLAMMATORY DISEASES AND PREPARATION THEREOF | 智泽童康(广州)生物科技有限公司 | 2024-06-20 | — | — | WO | claimed |
| EP-4112053-B1 | TREATMENT OF SYNUCLEINOPATHIES | DEUTSCHES ZENTRUM FUER NEURODEGENERATIVE ERKRANKUNGEN E V DZNE (DE) | 2024-02-14 | — | — | EP | claimed |
| CN-116368243-A | Replication stress pathway agent compositions and methods for treating cancer | 无界生物公司 | 2023-06-30 | — | — | CN | claimed |
| EP-3058942-B2 | COMPOSITIONS COMPRISING UNSATURATED FATTY ACIDS AND NITRIC OXIDE RELEASING COMPOUNDS AND USE THEREOF FOR ENHANCING COGNITIVE AND RELATED FUNCTIONS | NESTLE SA (CH) | 2023-03-22 | — | — | EP | claimed |
| CN-115634226-A | Method for treating myopia by vinpocetine | 温州医科大学附属眼视光医院 | 2023-01-24 | — | — | CN | claimed |
| US-20220218630-A1 | METHODS AND FORMULATIONS FOR TREATING VISION DISORDERS | JENIVISION INC. | 2022-07-14 | — | — | US | claimed |
| EP-3525788-B1 | TREATMENT OF SYNUCLEINOPATHIES | DEUTSCHES ZENTRUM FUER NEURODEGENERATIVE ERKRANKUNGEN E V DZNE (DE) | 2022-05-25 | — | — | EP | claimed |
| EP-3979996-A1 | METHODS AND FORMULATIONS FOR TREATING VISION DISORDERS | Jenivision Inc. (US) | 2022-04-13 | — | — | EP | claimed |
| CN-122031694-A | Pharmaceutical composition for overcoming drug resistance of lenvatinib and application thereof | 贵港市人民医院 | 2026-05-15 | — | — | CN | disclosed |
| US-20260115256-A1 | HUMAN AMYLIN ANALOG, AND DERIVATIVE THEREOF AND USE THEREOF | HANGZHOU SCIWIND BIOSCIENCES CO., LTD. (CN) | 2026-04-30 | — | — | US | disclosed |
| EP-3662281-B1 | CELL-SUBSTRATE IMPEDANCE MONITORING OF CANCER CELLS OF DIFFERENT LINEAGE, ORIGIN, OR STAGE | AGILENT TECHNOLOGIES INC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260055116-A1 | SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | KARUNA THERAPEUTICS INC (US) | 2026-02-26 | — | — | US | disclosed |
| EP-4688761-A1 | (S)-TIANEPTINE AND USE IN TREATING DISORDERS AND CONDITIONS ASSOCIATED WITH PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR | Tonix Pharma Limited (IE) | 2026-02-11 | — | — | EP | disclosed |
| CN-109641898-B | 5, 7-dihydro-pyrrolo-pyridine derivatives for the treatment of neurological and neurodegenerative diseases | 辉瑞公司 | 2022-04-08 | — | — | CN | disclosed |
| CN-112649522-B | Method for detecting related substances vinblastic acid and apovincamine acid in injection | 海南葫芦娃药业集团股份有限公司 | 2022-02-22 | — | — | CN | disclosed |
| US-20220033780-A1 | METHOD FOR PREPARING INTESTINAL ORGANOID DERIVED FROM PLURIPOTENT STEM CELL | PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY (JP) | 2022-02-03 | — | — | US | disclosed |
| US-11234933-B1 | Surface-modified emulsomes for intranasal delivery of drugs | KING ABDULAZIZ UNIVERSITY (SA) | 2022-02-01 | — | — | US | disclosed |
| CN-113993511-A | Methods and formulations for treating visual disorders | 杰尼视界公司 | 2022-01-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312340-A1 | METHODS OF TREATING NEUROPATHIC PAIN | GAP43, OPRK1, CNR2 | PDE1A 389/4885MEN1 3652/4885LMNA 2354/4885 |
| US-20260055116-A1 | SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | CHRM3, CHRM2, CHRM1 | PDE1A 1076/4885MEN1 3715/4885LMNA 4175/4885 |
| US-20260115256-A1 | HUMAN AMYLIN ANALOG, AND DERIVATIVE THEREOF AND USE THEREOF | IAPP, GLP1R, GIPR | PDE1A 1682/4885MEN1 2960/4885LMNA 1158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.